ASCLETIS-B (01672) saw a rebound of nearly 3%, rising 2.01% to HK$13.2 by the time of writing, with a trading volume of HK$31.84 million.

On December 15, ASCLETIS-B announced positive topline results from a randomized, double-blind, placebo-controlled Phase I clinical trial (NCT07024602) conducted in the U.S. for ASC50. The study, a single ascending dose (SAD) trial in healthy volunteers, evaluated the safety, tolerability, pharmacokinetics, and interleukin-17A (IL-17A) target engagement in peripheral circulation.

A total of 46 healthy participants received doses of 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg of ASC50 or a matching placebo. The study aimed to assess safety, tolerability, pharmacokinetics, and target engagement.

ASC50 is an orally administered small-molecule IL-17 inhibitor independently developed by ASCLETIS. IL-17 has been biologically validated in multiple autoimmune and inflammatory diseases, including psoriasis, and holds established commercial value. ASC50 is a new chemical entity (NCE) with U.S. and global compound patent protection extending until 2043 (excluding potential patent extensions).